CCR5
ENSG00000160791
Target class
GPCR
Chromosome
3
Approved drugs
1
Clinical candidates (approved and in development)
12
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- Yes
- Target name
- CCR5
- Gene name
- C-C motif chemokine receptor 5
- Gene symbol
- CCR5
- Previous gene symbols
- CMKBR5
- Protein name
- C-C chemokine receptor type 5 (C-C CKR-5) (CC-CKR-5) (CCR-5) (CCR5) (CHEMR13) (HIV-1 fusion coreceptor) (CD antigen CD195)
- CKR-5
- CC-CKR-5
- CKR5
- CD195
- IDDM22
- Gene biotype
- Protein coding
- Gene family
- CD molecules|C-C motif chemokine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 16
- Highest tissue expression
- 8.85
- Tissue specificity (Gini)
- 0.565
- Tissue specificity (tau)
- 0.907
- KEGG gene identifiers
- hsa:1234
- Protein interaction confidence
- 0.867087
- Protein interaction partners
- 149
- R-HSA-173107
- R-HSA-380108
- R-HSA-418594
- R-HSA-6783783
- End position
- 46376206
- Start position
- 46370946
- Chromosome
- 3
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 10383387
- PubMed 11323418
- Tissue specificity (tau)
- 0.907238
- Expression inequality (Gini)
- 0.564907
Expression in transcripts per million
- Spleen
- 8.85
- Lung
- 4.49
- Small Intestine - Terminal Ileum
- 4.24
- Whole Blood
- 2.74
- Cervix - Endocervix
- 1.82
Expression in transcripts per million
- Spleen8.85
- Lung4.49
- Small Intestine - Terminal Ileum4.24
- Whole Blood2.74
- Cervix - Endocervix1.82
- Fallopian Tube1.74
- Minor Salivary Gland1.4
- Colon - Transverse1.39
- Bladder1.37
- Prostate1.33
- Stomach1.33
- Adipose - Visceral (Omentum)1.3
- Brain - Spinal cord (cervical c-1)1.29
- Artery - Coronary1.25
- Thyroid1.15
- Nerve - Tibial1.13
- Esophagus - Mucosa0.94
- Artery - Aorta0.93
- Adipose - Subcutaneous0.91
- Vagina0.87
- Uterus0.85
- Adrenal Gland0.83
- Cervix - Ectocervix0.77
- Colon - Sigmoid0.75
- Esophagus - Muscularis0.7
And 29 more, listed on the interactive page.
- GO:0000165
- GO:0002407
- GO:0006816
- GO:0006935
- GO:0006954
- GO:0006955
- GO:0006968
- GO:0007166
- GO:0007186
- GO:0007204
- GO:0007267
- GO:0014808
- GO:0019722
- GO:0023052
- GO:0070723
- GO:0071222
- GO:0005737
- GO:0005768
- GO:0005886
- GO:0009897
- GO:0009986
- GO:0001618
- GO:0003779
- GO:0004435
- GO:0004950
- GO:0005515
- GO:0015026
- GO:0016493
- GO:0019957
- GO:0042802
- GO:0071791
Related records
Trials (298)
- A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals
- A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers
- A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
- A Compassionate Use Study of Leronlimab in Breast Cancer
- A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
- A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
- A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants
- A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
- A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
- A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients
- A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects
- A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
- A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
- A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers
- A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
- A Phase 2 Study Of PF-00232798 In HIV Positive Patients
- A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
- A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability
- A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
- A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
Drugs (14)
- Aplaviroc C-C chemokine receptor type 5 antagonist
- Aplaviroc hydrochloride C-C chemokine receptor type 5 antagonist
- AZD5672 C-C chemokine receptor type 5 antagonist
- BMS-813160 C-C chemokine receptor type 5 antagonist
- CCR5MAB004 C-C chemokine receptor type 5 inhibitor
- Cenicriviroc C-C chemokine receptor type 5 antagonist
- HGS-1025 C-C chemokine receptor type 5 inhibitor
- INCB-9471 C-C chemokine receptor type 5 antagonist
- Leronlimab C-C chemokine receptor type 5 antagonist
- Maraviroc C-C chemokine receptor type 5 antagonist
- PF-04634817 C-C chemokine receptor type 5 antagonist
- PF-232798 C-C chemokine receptor type 5 inhibitor
- Vicriviroc C-C chemokine receptor type 5 antagonist
- Vicriviroc maleate C-C chemokine receptor type 5 antagonist